公开(公告)号：US20200009147A1

公开(公告)日：2020-01-09

申请号：US16483079

申请日：2018-02-01

Applicant: LEO Pharma A/S

Inventor： Mogens LARSEN ,  Andreas RITZEN ,  Bjarne NØRREMARK ,  Daniel Rodriguez GREVE

IPC: A61K31/519 ,  C07D487/04

Abstract: The present invention relates to a compound according to formula I wherein X represents NH or 0; n is an integer selected from 1-3; Y represents a bond, —C(O)O—*, —C(O)OR3—* or —C(O)NHR3—*; W is selected from the group consisting of phenyl, pyridyl, (C3-C7)cycloalkyl and 4-6 membered heterocycloalkyl; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20210079012A1

公开(公告)日：2021-03-18

申请号：US16772615

申请日：2018-12-14

Applicant: LEO Pharma A/S

Inventor： Mark ANDREWS ,  Daniel Rodriguez GREVE ,  Bjarne NØRREMARK

IPC: C07D495/04

Abstract: The present invention relates to novel substituted azetidine dihydrothienopyridines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I)